Full-Time

Associate Director

Clinical Scientist, Oncology

Confirmed live in the last 24 hours

Eikon Therapeutics

Eikon Therapeutics

201-500 employees

Biotech startup developing innovative medicines

Compensation Overview

$189k - $206.2kAnnually

+ Bonus + Equity Compensation

Senior, Expert

San Bruno, CA, USA + 2 more

More locations: New York, NY, USA | Hayward, CA, USA

The position requires a minimum of 3 days a week of onsite presence in either Jersey City, New York City, or Millbrae, CA.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Data Analysis
Google Cloud Platform
Requirements
  • 10+ years of experience with a Bachelor's degree, or 8+ years with a post graduate degree
  • Solid knowledge of clinical research regulatory requirements (e.g., GCP and ICH)
  • Ability to manage multiple competing priorities with good planning, time management and prioritization skills
  • Strong analytical skills with the ability to interpret clinical trial data and synthesize conclusions
  • Proficient scientific expertise to propose, design, and execute clinical research and development studies, and authors documents related to clinical trials, such as medical monitoring plan, SAPs, informed consent and clinical components of the Clinical Study Reports
  • Role requires proactive approach, strategic thinking and leadership in driving toward clinical study goals
  • Influence opinions and decisions of internal and external customers / vendors, across functional areas
  • Problem solving, prioritization, conflict resolution and critical thinking skills
  • Strong communication, technical writing, and presentation skills experience
Responsibilities
  • Responsible for leading specific aspects of clinical/scientific execution of clinical protocol(s)
  • Serving as the lead clinical scientist on the clinical trial team
  • Leading medical monitoring team in review and interpretation of clinical data/medical protocol deviations in collaboration with Clinical Research and Pharmacovigilance
  • Collaborating cross-functionally in the development of Protocol and related study materials (e.g., ICF documents / amendments); partnering with Clinical Operations on study deliverables
  • Ensure CRF design supports data collection in alignment with the Protocol in collaboration with Clinical Data Management/Programming
  • Collaborating cross-functionally to monitor clinical data to ensure quality, completeness, and integrity of trial conduct
  • Providing tactical/scientific mentorship to other clinical scientists
  • Responsible for assisting with the generation, analysis, and presentation of clinical data, including manuscripts, abstracts, and oral presentations (including authoring documents and slide preparation as appropriate)
  • Apply proficient analytical knowledge and skills to understand how program objectives and design impact data analysis; identifies risks and designs mitigation strategies
  • Promotes consistent first line medical/clinical data review techniques and conventions across studies/programs.
Desired Qualifications
  • Experience in clinical drug development experience, or a PhD, Pharm D, or RN degree is preferred
  • Experience within oncology preferred

Eikon Therapeutics focuses on discovering and developing new medicines in the pharmaceutical industry. The company employs advanced technologies to study biological systems, aiming to identify new drug targets by examining the dynamic aspects of biology rather than just static chemical processes. Their team consists of diverse professionals, including data scientists, chemists, and engineers, which allows them to combine science and engineering to create new therapies that improve and extend life. A key feature of their approach is a proprietary single-molecule tracking (SMT) platform that visualizes protein motion in living cells, enabling them to analyze molecular interactions with high precision. Eikon Therapeutics aims to serve patients with serious diseases by developing effective treatments and generates revenue through the commercialization of these therapies.

Company Size

201-500

Company Stage

Series D

Total Funding

$1.1B

Headquarters

Hayward, California

Founded

2019

Simplify Jobs

Simplify's Take

What believers are saying

  • Eikon raised $350.7 million in Series D funding, supporting cancer drug development.
  • The SMT platform aligns with the growing demand for precision medicine and personalized therapies.
  • Eikon's AI-driven platform enhances drug discovery, leveraging the trend of AI in biotech.

What critics are saying

  • Increased competition from biotech unicorns like Abogen Biosciences with significant funding.
  • Potential challenges in scaling operations, evidenced by a large office lease in Jersey City.
  • Pressure to deliver on high expectations following substantial Series D funding.

What makes Eikon Therapeutics unique

  • Eikon's SMT platform offers real-time, molecular-resolution measurements of protein movement in living cells.
  • The company integrates AI and advanced automation for large-scale molecular interaction analysis.
  • Eikon's diverse team combines expertise in science, engineering, and technology for innovative therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Company Match

Medical (premiums covered by Eikon at 95%)

Dental Insurance

Vision Insurance

Mental Health Support

Unlimited Paid Time Off

Paid Holidays

Life Insurance

Enhanced Parental Leave

Daily subsidized lunch program

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

5%
Chronicles Magazine
Mar 3rd, 2025
Family office investors demonstrate appetite for innovation and diversity

Another significant entity, Soros Capital - managed by Robert Soros, son of the billionaire George Soros - participated in a $350.7 million financing round for Eikon Therapeutics.

Business Wire
Feb 27th, 2025
Eikon Therapeutics Secures $350.7 Million Series D to Advance Clinical-Stage Programs and Future Pipeline

Eikon Therapeutics, Inc., a pivotal-stage biotechnology company that integrates advanced engineering with cutting-edge molecular and cell biology to a

Stat News
Feb 26th, 2025
Eikon Therapeutics raises $350 million

Eikon Therapeutics, led by former Merck RD head Roger Perlmutter, raised $350 million, bringing its total funding to $1.1 billion. The funds will support the clinical development of cancer drugs, including an immunotherapy in Phase 3 for melanoma and two PARP inhibitors. The financing round included investors like Lux Capital and Alexandria Venture Investments.

BioWorld
Feb 26th, 2025
Eikon raises $350.7M in Series D

Eikon Therapeutics Inc. has closed a $351 million series D funding round, marking the largest venture capital round of 2025 and the first series D of the year. This funding supports Eikon as it enters phase III in cancer treatment development.

Business Wire
Jan 7th, 2025
Eikon Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Eikon Therapeutics to present at the 43rd Annual J.P. Morgan Healthcare Conference.